As EML4-ALK fusion is not as frequent as EGFR gene mutation, it would be important to efficiently and accurately identify those lung adenocarcinomas that harbor ALK rearrangements in clinical practice to guide the appropriate therapy. The gene discussed is EGFR; the disease is lung adenocarcinoma.